The impact of intra-articular methylprednisolone acetate injection on fructosamine levels in diabetic patients with osteoarthritis of the knee, a case-control study

Autor: Haneen Jabaly-Habib, Suheil Artul, Fahed Sakas, Fadi Khazin, Geries Hakim, George Habib, Adel Jabbour
Rok vydání: 2016
Předmět:
Blood Glucose
Male
medicine.medical_specialty
Type 2 diabetes
Osteoarthritis
Methylprednisolone
Injections
Intra-Articular
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Rheumatology
Internal medicine
Diabetes mellitus
medicine
Humans
Treatment Failure
030212 general & internal medicine
Israel
Physical Therapy Modalities
Aged
Glycated Hemoglobin
030203 arthritis & rheumatology
medicine.diagnostic_test
business.industry
Anti-Inflammatory Agents
Non-Steroidal
Complete blood count
General Medicine
Middle Aged
Osteoarthritis
Knee
Methylprednisolone acetate
medicine.disease
Methylprednisolone Acetate
Surgery
C-Reactive Protein
Fructosamine
Diabetes Mellitus
Type 2
chemistry
Case-Control Studies
Erythrocyte sedimentation rate
Multivariate Analysis
Linear Models
Female
Lipid profile
business
Zdroj: Clinical Rheumatology. 35:1609-1614
ISSN: 1434-9949
0770-3198
Popis: Fructosamine is a glycated protein that reflects blood glucose control over the last 2-3 weeks. There are no studies that address the impact of intra-articular injection (IAI) of methylprednisolone acetate (MPA) on fructosamine levels among patients with type-2 diabetes and osteoarthritis of the knee (OAK). Non-selected patients attending the rheumatology or orthopedic clinic with type-2 diabetes and painful OAK, who failed non-steroidal anti-inflammatory drugs (NSAIDS) and physical therapy, were asked to participate in our study. After consent blood tests were drown for fructosamine, hemoglobin A1c (HbA1c) level, complete blood count, lipid profile, serum albumin, serum protein, c-reactive protein, and erythrocyte sedimentation rate. Demographic and different clinical parameters were also documented. Immediately after that, patients had IAI of 80 mg of MPA at the knee joint (group 1). Two to three weeks later, the same blood tests were repeated (except for HbA1c). Age- and sex-matched group of patients with type-2 diabetes and painful OAK attending the same clinics, but who were managed by NSAIDS were asked to participate as a control group (group 2) and had the same evaluation at enrollment and 2-3 weeks later, after consent. Eighteen patients from either group completed the study. Mean fructosamine level in group 1 patients was 263.7 ± 31.8 mg% prior to the IAI vs. 274.6 ± 39.3 mg% (p = 0.035), 2-3 weeks later, while mean fructosamine level in the control group (group 2) at enrollments was 274.2 ± 31.2 mg% vs. 269 ± 30.2 mg%, p = 0.509, 2-3 weeks later. There was no significant change in any other parameter tested at enrollment in either group, compared to those obtained 2-3 weeks afterwards. Body mass index was on the edge of significance as a predictor for a significant change in fructosamine level in group 1 patients. IAI of 80 mg of MPA in patients with type-2 diabetes and OAK had resulted in a significant, though mild increase in fructosamine levels 2-3 weeks later.
Databáze: OpenAIRE
Externí odkaz: